J Turk Acad Dermatol 2013; 7 (4): 1374R1

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Review DOI: 10.6003/jtad.1374r1 Dermatologic Manifestations of Neurologic Disease Ümit Türsen,* MD, Belma Türsen,** MD Address: *Mersin University, Medical Faculty, Dermatology Department, **Mersin Hospital, Dermatology Department, Mersin, Turkey. E-mail: [email protected] * Corresponding Author: Dr Ümit Türsen, Mersin University, Medical Faculty, Dermatology Department, 33079- Mersin Published: J Turk Acad Dermatol 2013; 7 (4): 1374r1. This article is available from: http://www.jtad.org/2013/4/jtad1374r1.pdf Key Words: Dermatology, manifestation, neurology Abstract Background: Many diseases present with both neurologic and dermatologic manifestations. Eight such clinical cases are presented, along with clinical photographs of the skin lesions, in the format of a self-evaluation. Each case is followed by a discussion and a brief review of the characteristic cutaneous and neurologic findings. The intent is to demonstrate classic dermatologic manifestations of diseases seen by neurologists. Introduction light the more common skin changes that occur in association with stroke, peripheral Many disorders have a combination of neurologic and dermatologic findings in neuropathy, meningitis, encephalitis, malig- patients. This manuscript provides an nancy and HIV. overview of neurocutaneous disorders and organizes them into clinically relevant groups In addition, we cover the most frequently of use to the practicing physician. Many encountered neurocutaneous conditions and neurological conditions are accompanied by finally, we will remind the reader of skin skin changes, which frequently appear before changes associated with adverse reactions to the onset of the neurological symptoms. In drugs commonly used by neurologists. This some cases a rash may herald the start of an article aims to cover the most important and infectious process. In others, skin changes meaningful dermatological disorders that you may mirror pathological processes that are also occurring in the brain or peripheral may encounter within neurology. An ex- nerves. Careful examination of the skin can haustive list of all potential cutaneous findings therefore provide important clues when would not necessarily be useful in diagnosis making a neurological diagnosis, allowing early and management; rather, we aim to provide a treatment and avoiding unnecessary tests. practical selection of management altering Instead of presenting an exhaustive list of dermatological signs within the context of cutaneous manifestation of every neurological condition, we aim to provide practical common neurological presentations. We also knowledge for the non-dermatologist to aid review some commonly encountered neuro- neurological differential diagnosis. We high- cutaneous disorders, skins lesions at different Page 1 of 19 (page number not for citation purposes) J Turk Acad Dermatol 2013; 7 (4): 1374r1. http://www.jtad.org/2013/4/jtad1374r1.pdf stages of HIV/AIDS and remind the reader of Telangiectasias are best seen on the lips, ton- important drug reactions [1,2]. gue, nose and fingers [1]. 4. Angiokeratomata: It is characterised by small red or black vascular malformations. A-Neurocutaneous Disorders Associated Fabry's disease is a rare X linked recessive With Stroke disorder caused by a deficit in the enzyme In young patients, the skin can provide im- α-galactosidase, resulting in deposition of portant clues as to the cause of stroke [1,2]. glycolipids in blood vessels and various or- There are some skin manifestations in pati- gans. There is multisystem involvement. ents with stroke as belows; Typically patients are male, presenting in childhood or early adolescence with painful 1.Livedo reticularis (Cutis marmorata): It neuropathy and in adulthood with ischae- is characterised by mottled red–blue disco- mic strokes. Discrete angiokeratomata ap- louration, net-like appearance, especially pear in a ‘bathing suit’ distribution early in over the legs, and exacerbated by cold. Livedo disease and usually before any neurological reticularis is not uncommon in young women symptoms [1]. and can be completely benign. However, it 5. Lax stretchy skin/hypermobility: Pseu- may indicate an underlying hyperviscosity doxanthoma elasticum is associated with syndrome or vasculitis. It appears in 25% of premature atherosclerosis and aneurysm those with systemic lupus erythematosus formation. It manifests cutaneously as patc- and antiphospholipid syndrome and is a hes of lax redundant skin like plucked chic- common association of vasculitis involving ken appearance, typically around the neck medium sized vessels like polyarteritis no- and inguinal folds. Arterial dissection and dosa and small sized vessels like cryoglobuli- aneurysm formation also occur in Ehlers– nemia. Sneddon's syndrome is characterised Danlos syndrome type IV as a result of de- by widespread livedo reticularis in associa- fective collagen, which causes thin trans- tion with multiple strokes. Here, patients lucent skin, easy bruising and joint hyper- tend to have high titres of antiphospholipid mobility [2]. antibodies and typically livedo reticularis de- 6. Xanthomata and xanthelasmata: It is velops several years before stroke. Patients characterised by yellow papules and plaques with polycythaemia may appear plethoric with cholesterol deposits [2]. and, in addition to livedo, often complain of itchy skin, especially when exposed to warm 7. Varicella zoster infections: On rare oc- water [3]. casions following trigeminal shingles, vari- cella zoster virus may infect arteries in close 2. Purpura: Purpura is non-blanching red or proximity to the trigeminal ganglion and purple macular lesions. A petechia is a small, cause ischaemic stroke [2]. less than 1-2 mm diameter, red or purple spot on the body, caused by a minor hemorr- 8. Diabetic skin manifestations: Dermato- hage. Purpura and petechia from bleeding be- logical examination can also provide clues to neath the skin are common in the older the more common risk factors for stroke. patient but may be significant in young pati- Dyslipidemia commonly manifests in the ents with stroke. Frequently, this indicates skin, especially familial forms. Neurologist small vessel vasculitis and platelet disorders, should look specifically for tendon xantho- including thrombotic thrombocytopenic pur- mata, xanthelasmata, eruptive xanthomata pura [2]. and palmar striae. And they do not forget to look for nicotine stained fingers and hair. 3. Telangiectasia: Telangiectasia is small Diabetes mellitus has many cutaneous mani- vascular lesions, prone to haemorrhage. He- festations, including necrobiosis lipoidica dia- reditary haemorrhagic telangiectasia is cha- beticorum (a well demarcated waxy yellow/ racterised by telangiectasia of the skin and brown plaque, usually on the shins, with sur- mucosal linings of the nose and gastrointes- face telangiectasia and ulceration), non-spe- tinal tract, with brain involvement in 10% of cific dermopathy (red/brown discolouration cases. Most patients complain of nosebleeds. often over the knees), blisters or acanthosis Page 2 of 19 (page number not for citation purposes) J Turk Acad Dermatol 2013; 7 (4): 1374r1. http://www.jtad.org/2013/4/jtad1374r1.pdf nigricans (velvety pigmented skin in body the first event. Patients without antibodies, folds) [2]. who had recurrent abortions as their first event, were at lowest risk. The study reported that recurrent events are of the same type as Antiphospholipid Syndrome the presenting symptom. Therefore, initial cli- Antiphospholipid syndrome is a hypercoagu- nical features can help predict the prognosis lable state resulting from antibodies that ne- of the disorder. Specific clinical features tend utralize anionic phospholipids on endothelial to cluster during the course of the disease. A cells and platelets. It is a multisystemic disor- variety of therapies have been tried. Use of der, and patients may present with a wide long-term anticoagulants to maintain the in- range of neurologic manifestations, fetal loss, ternational normalized ratio at 3 or greater mild thrombocytopenia, valvular heart di- may help prevent recurring thromboembo- sease, and livedo reticularis. Antiphospholi- lism. Aspirin is of clinical benefit and may pid syndrome is associated strongly with help decrease the incidence of fetal loss in systemic lupus erythematosus (SLE) and pa- some patients. Plasmapheresis and cyclop- tients with SLE are considered to have secon- hosphamide have been used. Ancrod (purified dary antiphospholipid syndrome. The term pit viper venom) has been used successfully primary antiphospholipid syndrome is reser- in one patient. A review of clinical and labo- ved for cases of unknown etiology. The disor- ratory characteristics of 50 patients by Asher- der is characterized by high titers of anti- son et al described a 70% survival rate in phospholipid antibodies (APLA), ie, lupus an- patients treated with anticoagulation, stero- ticoagulant and anticardiolipin antibodies. ids, and treatments that decrease antiphosp- Studies suggest that antibodies are not direc- holipid antibodies, such as plasmapheresis ted against phospholipids but are directed at and/or intravenous IgG. Statins have been phospholipid-binding proteins such as B2- used in antiphospholipid syndrome because glycoprotein I and prothrombin. The cuta- of their antithrombotic, anti-inflammatory, neous manifestations most commonly seen and pleiotropic effects on vascular endothe- include livedo reticularis and leg ulceration. lium. Statins may block
Recommended publications
  • Clinical Dermatology Notice

    Clinical Dermatology Notice

    This page intentionally left blank Clinical Dermatology Notice Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The editors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the editors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of such information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs. a LANGE medical book Clinical Dermatology Carol Soutor, MD Clinical Professor Department of Dermatology University of Minnesota Medical School Minneapolis, Minnesota Maria K. Hordinsky, MD Chair and Professor Department of Dermatology University of Minnesota Medical School Minneapolis, Minnesota New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi San Juan Seoul Singapore Sydney Toronto Copyright © 2013 by McGraw-Hill Education, LLC.
  • Cutaneous Manifestations of Systemic Disease

    Cutaneous Manifestations of Systemic Disease

    Cutaneous Manifestations of Systemic Disease Dr. Lloyd J. Cleaver D.O. FAOCD FAAD Northeast Regional Medical Center A.T.Still University/KCOM Assistant Vice President/Professor ACOI Board Review Disclosure I have no financial relationships to disclose I will not discuss off label use and/or investigational use in my presentation I do not have direct knowledge of AOBIM questions I have been granted approvial by the AOA to do this board review Dermatology on the AOBIM ”1-4%” of exam is Dermatology Table of Test Specifications is unavailable Review Syllabus for Internal Medicine Large amount of information Cutaneous Multisystem Cutaneous Connective Tissue Conditions Connective Tissue Diease Discoid Lupus Erythematosus Subacute Cutaneous LE Systemic Lupus Erythematosus Scleroderma CREST Syndrome Dermatomyositis Lupus Erythematosus Spectrum from cutaneous to severe systemic involvement Discoid LE (DLE) / Chronic Cutaneous Subacute Cutaneous LE (SCLE) Systemic LE (SLE) Cutaneous findings common in all forms Related to autoimmunity Discoid LE (Chronic Cutaneous LE) Primarily cutaneous Scaly, erythematous, atrophic plaques with sharp margins, telangiectasias and follicular plugging Possible elevated ESR, anemia or leukopenia Progression to SLE only 1-2% Heals with scarring, atrophy and dyspigmentation 5% ANA positive Discoid LE (Chronic Cutaneous LE) Scaly, atrophic plaques with defined margins Discoid LE (Chronic Cutaneous LE) Scaly, erythematous plaques with scarring, atrophy, dyspigmentation DISCOID LUPUS Subacute Cutaneous
  • Copyrighted Material

    1 Index Note: Page numbers in italics refer to figures, those in bold refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58. A definition 87.2 congenital ichthyoses 65.38–9 differential diagnosis 90.62 A fibres 85.1, 85.2 dermatomyositis association 88.21 discoid lupus erythematosus occupational 90.56–9 α-adrenoceptor agonists 106.8 differential diagnosis 87.5 treatment 89.41 chemical origin 130.10–12 abacavir disease course 87.5 hand eczema treatment 39.18 clinical features 90.58 drug eruptions 31.18 drug-induced 87.4 hidradenitis suppurativa management definition 90.56 HLA allele association 12.5 endocrine disorder skin signs 149.10, 92.10 differential diagnosis 90.57 hypersensitivity 119.6 149.11 keratitis–ichthyosis–deafness syndrome epidemiology 90.58 pharmacological hypersensitivity 31.10– epidemiology 87.3 treatment 65.32 investigations 90.58–9 11 familial 87.4 keratoacanthoma treatment 142.36 management 90.59 ABCA12 gene mutations 65.7 familial partial lipodystrophy neutral lipid storage disease with papular elastorrhexis differential ABCC6 gene mutations 72.27, 72.30 association 74.2 ichthyosis treatment 65.33 diagnosis 96.30 ABCC11 gene mutations 94.16 generalized 87.4 pityriasis rubra pilaris treatment 36.5, penile 111.19 abdominal wall, lymphoedema 105.20–1 genital 111.27 36.6 photodynamic therapy 22.7 ABHD5 gene mutations 65.32 HIV infection 31.12 psoriasis pomade 90.17 abrasions, sports injuries 123.16 investigations 87.5 generalized pustular 35.37 prepubertal 90.59–64 Abrikossoff
  • Dermatological Indications of Disease - Part II This Patient on Dialysis Is Showing: A

    Dermatological Indications of Disease - Part II This Patient on Dialysis Is Showing: A

    “Cutaneous Manifestations of Disease” ACOI - Las Vegas FR Darrow, DO, MACOI Burrell College of Osteopathic Medicine This 56 year old man has a history of headaches, jaw claudication and recent onset of blindness in his left eye. Sed rate is 110. He has: A. Ergot poisoning. B. Cholesterol emboli. C. Temporal arteritis. D. Scleroderma. E. Mucormycosis. Varicella associated. GCA complex = Cranial arteritis; Aortic arch syndrome; Fever/wasting syndrome (FUO); Polymyalgia rheumatica. This patient missed his vaccine due at age: A. 45 B. 50 C. 55 D. 60 E. 65 He must see a (an): A. neurologist. B. opthalmologist. C. cardiologist. D. gastroenterologist. E. surgeon. Medscape This 60 y/o male patient would most likely have which of the following as a pathogen? A. Pseudomonas B. Group B streptococcus* C. Listeria D. Pneumococcus E. Staphylococcus epidermidis This skin condition, erysipelas, may rarely lead to septicemia, thrombophlebitis, septic arthritis, osteomyelitis, and endocarditis. Involves the lymphatics with scarring and chronic lymphedema. *more likely pyogenes/beta hemolytic Streptococcus This patient is susceptible to: A. psoriasis. B. rheumatic fever. C. vasculitis. D. Celiac disease E. membranoproliferative glomerulonephritis. Also susceptible to PSGN and scarlet fever and reactive arthritis. Culture if MRSA suspected. This patient has antithyroid antibodies. This is: • A. alopecia areata. • B. psoriasis. • C. tinea. • D. lichen planus. • E. syphilis. Search for Hashimoto’s or Addison’s or other B8, Q2, Q3, DRB1, DR3, DR4, DR8 diseases. This patient who works in the electronics industry presents with paresthesias, abdominal pain, fingernail changes, and the below findings. He may well have poisoning from : A. lead. B.
  • Table I. Genodermatoses with Known Gene Defects 92 Pulkkinen

    Table I. Genodermatoses with Known Gene Defects 92 Pulkkinen

    92 Pulkkinen, Ringpfeil, and Uitto JAM ACAD DERMATOL JULY 2002 Table I. Genodermatoses with known gene defects Reference Disease Mutated gene* Affected protein/function No.† Epidermal fragility disorders DEB COL7A1 Type VII collagen 6 Junctional EB LAMA3, LAMB3, ␣3, ␤3, and ␥2 chains of laminin 5, 6 LAMC2, COL17A1 type XVII collagen EB with pyloric atresia ITGA6, ITGB4 ␣6␤4 Integrin 6 EB with muscular dystrophy PLEC1 Plectin 6 EB simplex KRT5, KRT14 Keratins 5 and 14 46 Ectodermal dysplasia with skin fragility PKP1 Plakophilin 1 47 Hailey-Hailey disease ATP2C1 ATP-dependent calcium transporter 13 Keratinization disorders Epidermolytic hyperkeratosis KRT1, KRT10 Keratins 1 and 10 46 Ichthyosis hystrix KRT1 Keratin 1 48 Epidermolytic PPK KRT9 Keratin 9 46 Nonepidermolytic PPK KRT1, KRT16 Keratins 1 and 16 46 Ichthyosis bullosa of Siemens KRT2e Keratin 2e 46 Pachyonychia congenita, types 1 and 2 KRT6a, KRT6b, KRT16, Keratins 6a, 6b, 16, and 17 46 KRT17 White sponge naevus KRT4, KRT13 Keratins 4 and 13 46 X-linked recessive ichthyosis STS Steroid sulfatase 49 Lamellar ichthyosis TGM1 Transglutaminase 1 50 Mutilating keratoderma with ichthyosis LOR Loricrin 10 Vohwinkel’s syndrome GJB2 Connexin 26 12 PPK with deafness GJB2 Connexin 26 12 Erythrokeratodermia variabilis GJB3, GJB4 Connexins 31 and 30.3 12 Darier disease ATP2A2 ATP-dependent calcium 14 transporter Striate PPK DSP, DSG1 Desmoplakin, desmoglein 1 51, 52 Conradi-Hu¨nermann-Happle syndrome EBP Delta 8-delta 7 sterol isomerase 53 (emopamil binding protein) Mal de Meleda ARS SLURP-1
  • (2) October 2011\Protocol Book\Program-Speaker Page-Oc

    (2) October 2011\Protocol Book\Program-Speaker Page-Oc

    Chicago Dermatological Society October 2011 Monthly Educational Conference Program Information Continuing Medical Education Certification and Case Presentations Wednesday, October 12, 2011 David Fretzin Lecture Conference Host: Department of Dermatology University of Illinois at Chicago Chicago, Illinois University of Illinois at Chicago C UIC Student Center West (SCW) - 828 S. Wolcott Ave., 2nd Floor Registration, lectures, slide viewing, lunch and committee meetings C UIC Outpatient Care Center, Dermatology Clinic - 1801 W. Taylor, Suite 3E Patient viewing only (no registration at this location! Protocol books will be available.) UIC parking – Use the Wood Street Parking Structure, 1100 S. Wood at the intersection of (Wood & Grenshaw, just south of the UIC Outpatient Care Center) See reverse side for detailed campus map From the Eisenhower Expressway, exit at Ashland/Paulina. Proceed south on Ashland to Taylor. Turn west on Taylor approximately two blocks to Wood St. Turn south on Wood for the entrance to the parking lot. Program Conference Locations Student Center West (SCW) – 828 S. Wolcott, 2nd Floor Dermatology Clinic, 1801 W. Taylor St., Suite 3E 8:00 a.m. Registration Opens Student Center West, 2nd floor Foyer 9:00 a.m. - 10:00 a.m. Resident Lecture – SCW Chicago Room A-C "Spectrum of CD30+ Lymphoproliferative Diseases" Samuel Hwang, MD, PhD 9:30 a.m. - 10:45 a.m. Clinical Rounds Patient & Poster Viewing Dermatology Clinic, Suite 3E Slide Viewing Student Center West, Room 213 A/B 11:00 a.m. - 12:15 p.m. General Session - SCW Chicago Room A-C FRETZIN LECTURE: "An Update on Th17 Cells in Psoriasis" Samuel Hwang, MD, PhD 12:15 p.m.
  • 21 Genodermatoses

    21 Genodermatoses

    . 21 . 21.2 The Ichthyoses 21 Genodermatoses Although this chapter is devoted to genodermatoses, many acquired disorders are also considered when they seem to fit into the general clinical picture. For example, acquired forms of porokeratosis are considered along with the less common in- herited ones. Genodermatoses 21.1 MIM Code What..................................................................................... is the MIM Code? Victor A. McKusick, one of the giants of clinical human genetics, started using a numerical code when he began compiling his books entitled Mendelian Inheritance in Man. The books evolved into a website, OMIM (Online Mendelian Inheritance in Man), which today serves as the standard for clinical genetics and the most convenient way to acquire updated information on all genetic disorders. The MIM code is given throughout this book whenever it is relevant. The first digit identifies the pattern of diagnosis: 1 = autosomal dominant inheritance; 2 = auto- somal recessive inheritance; 3 = X-linked inheritance. .....................................................................................How to Use OMIM 1 Simply enter ONIM in Google or any search engine and you will land on OMIM—or enter www.ncbi.nlm.nih.gov/OMIM. 2 Search OMIM. 3 Enter the MIM code, or a key word or two if you are looking for a syndrome or set of findings. 4 You will see a list of disease descriptions likely to be relevant to your query; chose whichever ones seem most useful. 5 Now you can read an update about the disease, the gene, find extensive references, or be linked to Medline. 21.2 The Ichthyoses Overview..................................................................................... The primary ichthyoses are a heterogenous group of inherited disorders featuring ex- cessive scale.
  • Copyrighted Material

    1 Index Note: Page numbers in italics refer to figures, those in bold refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58. A definition 87.2 congenital ichthyoses 65.38–9 differential diagnosis 90.62 A fibres 85.1, 85.2 dermatomyositis association 88.21 discoid lupus erythematosus occupational 90.56–9 α-adrenoceptor agonists 106.8 differential diagnosis 87.5 treatment 89.41 chemical origin 130.10–12 abacavir disease course 87.5 hand eczema treatment 39.18 clinical features 90.58 drug eruptions 31.18 drug-induced 87.4 hidradenitis suppurativa management definition 90.56 HLA allele association 12.5 endocrine disorder skin signs 149.10, 92.10 differential diagnosis 90.57 hypersensitivity 119.6 149.11 keratitis–ichthyosis–deafness syndrome epidemiology 90.58 pharmacological hypersensitivity 31.10– epidemiology 87.3 treatment 65.32 investigations 90.58–9 11 familial 87.4 keratoacanthoma treatment 142.36 management 90.59 ABCA12 gene mutations 65.7 familial partial lipodystrophy neutral lipid storage disease with papular elastorrhexis differential ABCC6 gene mutations 72.27, 72.30 association 74.2 ichthyosis treatment 65.33 diagnosis 96.30 ABCC11 gene mutations 94.16 generalized 87.4 pityriasis rubra pilaris treatment 36.5, penile 111.19 abdominal wall, lymphoedema 105.20–1 genital 111.27 36.6 photodynamic therapy 22.7 ABHD5 gene mutations 65.32 HIV infection 31.12 psoriasis pomade 90.17 abrasions, sports injuries 123.16 investigations 87.5 generalized pustular 35.37 prepubertal 90.59–64 Abrikossoff
  • General Physical Examination for a Cardiovascular Patient

    General Physical Examination for a Cardiovascular Patient

    Published online: 2019-07-16 THIEME 42 Clinical Rounds General Physical Examination for a Cardiovascular Patient Jyotsna Maddury1 Shagun Aggarwal2 1Department of Cardiology, Nizam’s Institute of Medical Sciences Address for correspondence Jyotsna Maddury, MD, DM, FACC, (NIMS), Punjagutta, Hyderabad, Telangana, India FESC, FICC, Department of Cardiology, Nizam’s Institute of Medical 2Department of Medical Genetics, Nizam’s Institute of Medical Sciences (NIMS), Punjagutta, Hyderabad 500 082, Telangana, India Sciences (NIMS), Punjagutta, Hyderabad, Telangana, India (e-mail: [email protected]). Ind J Car Dis Wom 2019;4:42–49 The “innocent eye, which should see the world afresh, does Skin not see it at all.”1 1. Cyanosis and clubbing: Cyanosis and clubbing were The general physical examination is important in patients described in detail in earlier issues of this journal. with cardiovascular disease for specific diagnosis, to assess 2. Telangiectasia and hemangiomas: Cyanosis due to the severity and progression of the disease and, in some the right-to-left shunt through the pulmonary arterio- cases, even to know the therapeutic response. venous fistulas along with telangiectasia on the lips, tongue, and mucous is seen in Osler-Rendu-Weber General Appearance syndrome. Tight, shiny skin with telangiectasias is due to scleroderma. Endothelial cell malignancy is called Examination of the patient starts by observing the patient hemangiomas, which are different from the vascular when he/she enters the room. We have to pay attention to malformations (►Fig. 1). Cardiac lesions in scleroderma the patient’s functional age, posture, and general condi- are pulmonary arterial hypertension, myocardial, peri- tion. If the patient is suffering from acute pain, the severity cardial, and endocardial diseases.2 Even long exposure of the pain is perceived by seeing the face, the presence of to radiation such as in chronic total occlusion (CTO) diaphoresis, and posture he/she adapts.
  • Cutaneous Manifestations of Systemic Disease

    Cutaneous Manifestations of Systemic Disease

    Cutaneous Manifestations of Systemic Disease Dr. Lloyd J. Cleaver D.O. FAOCD Northeast Regional Medical Center A.T.Still University/KCOM Assistant Vice President/Professor ABOIM Board Review Disclosure I have no financial relationships to disclose I will not discuss off label use and/or investigational use in my presentation I do not have direct knowledge of AOBIM questions I have been granted approvial by the AOA to do this board review Dermatology on the AOBIM ”1-4%” of exam is Dermatology Table of Test Specifications is unavailable Review Syllabus for Internal Medicine Large amount of information Cutaneous Multisystem Cutaneous Connective Tissue Conditions Connective Tissue Diease Discoid Lupus Erythematosus Subacute Cutaneous LE Systemic Lupus Erythematosus Scleroderma CREST Syndrome Dermatomyositis Lupus Erythematosus Spectrum from cutaneous to severe systemic involvement Discoid LE (DLE) / Chronic Cutaneous Subacute Cutaneous LE (SCLE) Systemic LE (SLE) Cutaneous findings common in all forms Related to autoimmunity Discoid LE (Chronic Cutaneous LE) Primarily cutaneous Scaly, erythematous, atrophic plaques with sharp margins, telangiectasias and follicular plugging Possible elevated ESR, anemia or leukopenia Progression to SLE only 1-2% Heals with scarring, atrophy and dyspigmentation 5% ANA positive Discoid LE (Chronic Cutaneous LE) Scaly, atrophic plaques with defined margins Discoid LE (Chronic Cutaneous LE) Scaly, erythematous plaques with scarring, atrophy, dyspigmentation DISCOID LUPUS Subacute Cutaneous
  • An Osteopathic Approach to Raynaud's Phenomenon

    An Osteopathic Approach to Raynaud's Phenomenon

    Volume 27 JAOCDJournal Of The American Osteopathic College Of Dermatology pg. 12 An Osteopathic Approach to Raynaud’s Phenomenon Also in this issue: Tinea Faciei Presenting as a Perioral Dermatitis Cutaneous Pili Migrans Misdiagnosed Vicks VapoRub™ for Onychomycosis? last modified on December 19, 2013 2:08 PM JOURNAL OF THE AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY Page 1 JOURNAL OF THE AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY 2013-2014 AOCD OFFICERS PRESIDENT Suzanne Sirota-Rozenberg, DO, FAOCD PRESIDENT-ELECT Rick Lin, DO, FAOCD FIRST VICE-PRESIDENT Alpesh Desai, DO, FAOCD SECOND VICE-PRESIDENT Karthik Krishnamurthy, DO, FAOCD THIRD VICE-PRESIDENT Daniel Ladd, DO, FAOCD Editor-in-Chief IMMEDIATE PAST-PRESIDENT Karthik Krishnamurthy, DO Bradley Glick, DO, FAOCD SECRETARY-TREASURER Jere J. Mammino, DO, FAOCD TRUSTEES John P. Minni, DO, FAOCD Bryan Sands, DO, FAOCD Sponsors: Danica Alexander, DO, FAOCD Reagan Anderson, DO, FAOCD Bayer Michael Whitworth, DO, FAOCD AuroraDx Tracy Favreau, DO, FAOCD Immediate Past-President Medicis David L. Grice, DO, FAOCD Ranbaxy EEC Representatives James Bernard, DO, FAOCD JAOCD Michael Scott, DO, FAOCD Founding Sponsor Finance Committee Representative Steven K. Grekin, DO, FAOCD AOBD Representative Stephen Purcell, DO, FAOCD Executive Director AOCD • 2902 N. Baltimore St. • Kirksville, MO 63501 Marsha A. Wise, BS 800-449-2623 • FAX: 660-627-2623 • www.aocd.org COPYRIGHT AND PERMISSION: Written permission must be obtained from the Journal of the American Osteopathic College of Dermatology for copying or reprinting text of more than half a page, tables or figures. Permissions are normally granted contingent upon similar permission from the author(s), inclusion of acknowledgement of the original source, and a payment of $15 per page, table or figure of reproduced material.
  • Controversies in the Management of Digital Mucous Cysts

    Controversies in the Management of Digital Mucous Cysts

    Volume 30 JAOCDJournal Of The American Osteopathic College Of Dermatology Controversies in the Management of Digital Mucous Cysts Also in this issue: Squamous Cell Carcinoma in Situ Treated with Imiquimod Cream HIV-Associated Kaposi Sarcoma Induced by IRIS Psuedoxanthma Elasticum in Flexural and Non-Flexural Folds last modified on November 19, 2014 3:43 PM JOURNAL OF THE AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY Page 1 JOURNAL OF THE AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY 2013-2014 AOCD OFFICERS PRESIDENT Suzanne Sirota-Rozenberg, DO, FAOCD PRESIDENT-ELECT Rick Lin, DO, FAOCD FIRST VICE-PRESIDENT Alpesh Desai, DO, FAOCD SECOND VICE-PRESIDENT Karthik Krishnamurthy, DO, FAOCD THIRD VICE-PRESIDENT Daniel Ladd, DO, FAOCD Editor-in-Chief SECRETARY-TREASURER Karthik Krishnamurthy, DO Jere J. Mammino, DO, FAOCD TRUSTEES John P. Minni, DO, FAOCD Bryan Sands, DO, FAOCD Danica Alexander, DO, FAOCD Reagan Anderson, DO, FAOCD Sponsors: Michael Whitworth, DO, FAOCD Tracy Favreau, DO, FAOCD Bayer Immediate Past-President AuroraDx David L. Grice, DO, FAOCD EEC Representatives Ranbaxy James Bernard, DO, FAOCD Michael Scott, DO, FAOCD Valeant Finance Committee Representative Steven K. Grekin, DO, FAOCD AOBD Representative Stephen Purcell, DO, FAOCD Executive Director Marsha A. Wise, BS AOCD • 2902 N. Baltimore St. • Kirksville, MO 63501 800-449-2623 • FAX: 660-627-2623 • www.aocd.org COPYRIGHT AND PERMISSION: Written permission must be obtained from the Journal of the American Osteopathic College of Dermatology for copying or reprinting text of more than half a page, tables or figures. Permissions are normally granted contingent upon similar permission from the author(s), inclusion of acknowledgment of the original source, and a payment of $15 per page, table or figure of reproduced material.